Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,512,491
  • Shares Outstanding, K 175,274
  • Annual Sales, $ 1,193 M
  • Annual Income, $ 681,310 K
  • 60-Month Beta 2.62
  • Price/Sales 2.75
  • Price/Cash Flow 4.68
  • Price/Book 2.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.72
  • Number of Estimates 8
  • High Estimate -0.57
  • Low Estimate -0.86
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.64 +34.19%
on 10/15/19
22.48 -6.67%
on 11/11/19
+3.89 (+22.76%)
since 10/11/19
3-Month
15.64 +34.19%
on 10/15/19
22.48 -6.67%
on 11/11/19
+0.06 (+0.29%)
since 08/09/19
52-Week
15.64 +34.19%
on 10/15/19
47.11 -55.47%
on 02/11/19
-13.04 (-38.33%)
since 11/09/18

Most Recent Stories

More News
SmarTrend Watching for Potential Pullback in Shares of Nektar Therapeut After 31.00% Gain

Nektar Therapeut (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $20.64 to a high of $22.47. Yesterday, the shares gained 31.0%, which took the trading range above the 3-day high...

NKTR : 20.98 (+4.69%)
Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology

Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune...

NKTR : 20.98 (+4.69%)
Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer...

NKTR : 20.98 (+4.69%)
Shares of Supernus Pharmac Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (SUPN , NKTR , BMY , PCRX , JNJ )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

BMY : 58.15 (+0.22%)
NKTR : 20.98 (+4.69%)
SUPN : 21.84 (+0.58%)
Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up

Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain....

MRK : 83.28 (-0.37%)
LLY : 112.80 (-0.64%)
BMY : 58.15 (+0.22%)
NKTR : 20.98 (+4.69%)
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 23.29% and 11.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

NKTR : 20.98 (+4.69%)
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2019.

NKTR : 20.98 (+4.69%)
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Nektar Therapeut (NKTR , XENT , AERI , MYL , AGN )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

AERI : 19.05 (-0.94%)
XENT : 20.92 (-2.01%)
NKTR : 20.98 (+4.69%)
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at 9:00 a.m....

NKTR : 20.98 (+4.69%)
Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 6, 2019, after the close of U.S.-based financial markets. Howard Robin, President and...

NKTR : 20.98 (+4.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade NKTR with:

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

2nd Resistance Point 23.42
1st Resistance Point 22.20
Last Price 20.98
1st Support Level 20.04
2nd Support Level 19.10

See More

52-Week High 47.11
Fibonacci 61.8% 35.09
Fibonacci 50% 31.37
Fibonacci 38.2% 27.66
Last Price 20.98
52-Week Low 15.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar